Cord Blood News Volume 6.37 | Sept 25 2014

    0
    131

    Cord Blood News 6.37 September 25, 2014

    Cord Blood News

         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  CBN on Twitter

     
    TOP STORY
    World Breakthrough: A New Molecule Allows for an Increase in Stem Cell Transplants
    Investigators have the announced of the discovery of a new molecule, the first of its kind, which allows for the multiplication of stem cells in a unit of cord blood. This world breakthrough has the potential to multiply by ten the number of cord blood units available for a transplant in humans. [Press release from the University of Montreal discussing online publication in Science] Press Release | Abstract
    ​25% Off First Order: MNCs, CD34+ cells and more

     
    PUBLICATIONS (Ranked by impact factor of the journal)
    Melatonin Enhances the Human Mesenchymal Stem Cells Motility via Melatonin Receptor 2 Coupling with Gαq in Skin Wound Healing
    In a mouse skin excisional wound model, scientists found that transplantation of umbilical cord blood mesenchymal stem cells (UCB-MSCs) pre-treated with melatonin enhanced wound closure, granulation, and re-epithelialization at mouse skin wound sites, where relatively more UCB-MSCs which were engrafted onto the wound site were detected. [J Pineal Res] Abstract

    Paracrine Factors Secreted by Umbilical Cord Derived Mesenchymal Stem Cells Induce Angiogenesis In Vitro by a VEGF-Independent Pathway
    Researchers evaluated the presence of well-known pro-angiogenic factors in the conditioned media (CM) derived from umbilical cord derived-mesenchymal stem cells by ELISA. While VEGF was not detected in the CM, gene expression was nevertheless detected in these cells. [Stem Cells Dev] Abstract

    Mesenchymal Stromal Cells Derived from Blood Vessels or Avascular Tissues: What Is the Better Choice to Support Endothelial Cell Function?
    Investigators isolated and characterized mesenchymal stromal cells (MSC) from placental chorionic blood vessels and tested their angiogenic potential in comparison to amnion-derived avascular MSC. [Stem Cells Dev] Abstract

    Placental Mesenchymal Stem Cells of Fetal Origin Deposit Epigenetic Alterations during Long-Term Culture under Serum-Free Condition
    Fetal placental mesenchymal stem cells (fPMSCs) have shown promising cell therapy potential. However, their genetic and epigenetic stability during in vitro propagation has not been well studied. Investigators thus interrogated the methylation alterations and tumorigenicity of fPMSCs after in vitro expansion using serum-free medium. [Expert Opin Biol Ther] Abstract

    CD29 of Human Umbilical Cord Mesenchymal Stem Cells Is Required for Expansion of CD34+ Cells
    To investigate whether CD29 of human umbilical cord mesenchymal stem cells (hUCMSCs) would play a key role for the ability of hUCMSCs to expand hematopoietic stem cells, soluble anti-CD29 antibody was added to co-cultures of hUCMSCs and cord blood CD34+ cells. [Cell Prolif] Abstract

    Expanded Umbilical Cord Blood T Cells Used as Donor Lymphocyte Infusions after Umbilical Cord Blood Transplantation
    In vitro-cultured T cells from the umbilical cord blood (UCB) graft were explored as an alternative to conventional donor lymphocyte infusion (DLI). Scientists studied the safety of the cultured UCB T cells used as DLI because such cell preparations have not been used in this context previously. [Cytotherapy] Abstract

    Comparison of Umbilical Cord Blood Allogeneic Stem-Cell Transplantation (SCT) vs Auto-SCT for Adult Acute Myeloid Leukemia Patients in Second Complete Remission at Transplant: A Retrospective Study on Behalf of the SFGM-TC
    Investigators considered the outcomes of 181 acute myeloid leukemia patients transplanted in second complete remission who received either a myeloablative autologous SCT (auto-SCT) or an umbilical cord blood allogeneic SCT. [Eur J Haematol] Abstract

    Enhanced Human Mesenchymal Stem Cell Survival under Oxidative Stress by Overexpression of Secreted Frizzled-Related Protein 2 Gene
    Researchers investigated how to enhance the survival of human mesenchymal stem cells (hMSCs) under oxidative stress by overexpressing secreted frizzled-related protein 2 gene in bone marrow-derived hMSCs and umbilical cord-derived hMSCs. [Ann Hematol] Abstract

    The Functional Study of Human Umbilical Cord Mesenchymal Stem Cells Harboring Angiotensin-Converting Enzyme 2 in Rat Acute Lung Ischemia-Reperfusion Injury Model
    The authors aimed to find a more effective therapeutic approach to treat acute lung ischemia-reperfusion injury (ALIRI). They evaluated the combinational effects of human umbilical cord mesenchymal stem cells and angiotensin-converting enzyme 2 in the rat ALIRI model. [Cell Biochem Funct] Abstract

    Technical Bulletin: Assays For Cord Blood

     
    REVIEWS
    Allogeneic Stem-Cell Transplantation for Peripheral T-Cell Lymphoma: A Systemic Review and Meta-Analysis
    The authors performed a systemic review and meta-analysis examining the efficacy and safety of allogeneic stem cell transplantation for peripheral T-cell lymphoma. [Acta Haematol] Abstract

    Visit our reviews page to see a complete list of reviews in the cord blood research field.

     
    INDUSTRY NEWS
    Americord Backs Another Cord Blood Clinical Trial
    Americord announced that it has provided funding to support a clinical trial investigating the efficacy of autologous umbilical cord blood for the treatment of pediatric patients with cerebral palsy. [Americord Registry] Press Release

    Celldex Therapeutics Initiates Pilot Study of CDX-301 in Allogeneic Hematopoietic Stem Cell Transplantation
    Celldex Therapeutics, Inc. announced the initiation of a pilot study of CDX-301 for the mobilization and transplantation of allogeneic hematopoietic stem cells in patients with hematological malignancies undergoing hematopoietic stem cell transplantation. [Celldex Therapeutics, Inc.] Press Release

    From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.

     
    POLICY NEWS
    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

     
    EVENTS
    NEW Haematocon 2014 – 55th Annual Conference of Indian Society of Hematology & Blood Transfusion (ISHBT)
    November 6-8, 2014
    Hyderabad, India

    NEW CellTech India 2015
    March 2-3, 2015
    Bangalore, India

    Visit our events page to see a complete list of events in the cord blood community.

     
    JOB OPPORTUNITIES
    NEW Postdoctoral Position – Cell Signaling in Hematopoietic Stem Cells (Cincinnati Children’s Hospital Medical Center)

    Faculty Positions – Stem Cells and Regenerative Medicine (Baylor College of Medicine)

    PhD Positions – Stem Cells and Transplantation (University of Geneva)

    Postdoctoral Fellow – Hematopoietic Stem Cells and Signaling Transduction (University of Pennsylvania)

    Research Assistant – Ex Vivo Cord Blood Expansion (MD Anderson Cancer Center)

    Postdoctoral Positions – Hematopoietic and Induced Pluripotent Stem Cells (Indiana University School of Medicine)

    Postdoctoral Positions – Hematologic Malignancies and Cellular Therapy (Duke University Department of Medicine)

    Postdoctoral Fellowship – Developing Applications of Mesenchymal Stromal/Stem Cells in Hematopoietic Cell Transplantation (The Research Institute at Nationwide Children’s Hospital)

    Cord Tissue Processing Technician (Cord Blood Registry)

    Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

    Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

    Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

    Research Associate – Cell Separation (STEMCELL Technologies Inc.)


    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

     

    Have we missed an important article or publication in Cord Blood News? Click here to submit!

    Comments or suggestions? Submit your feedback here

    Learn more about Cord Blood News: Archives | Events | Contact Us